Serum proteomic profiles of depressive subtypes

Translational Psychiatry

Volumn 6, Issue 7, 2016, Pages

  Lamers, F ^a   Bot, M ^a   Jansen, R ^a   Chan, M K ^b   Cooper, J D ^b   Bahn, S ^b   Penninx, B W J H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; COMPLEMENT COMPONENT C3; FATTY ACID BINDING PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IGFBP-2 PROTEIN, HUMAN; IGFBP1 PROTEIN, HUMAN; INSULIN; LEPTIN; MESOTHELIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2;

ADULT; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; DEPRESSION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NETHERLANDS; PROTEOMICS; PSYCHOLOGY; STATISTICAL MODEL;

ADULT; BETA 2-MICROGLOBULIN; CASE-CONTROL STUDIES; COMPLEMENT C3; DEPRESSIVE DISORDER; FATTY ACID-BINDING PROTEINS; FEMALE; GPI-LINKED PROTEINS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LEPTIN; LINEAR MODELS; MALE; MIDDLE AGED; NETHERLANDS; PROTEOMICS;

EID: 85011914521     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.115     Document Type: Article

References (74)

1. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013; 18: 497–511.
2. Jansen R, Penninx BW, Madar V, Xia K, Milaneschi Y, Hottenga JJ et al. Gene expression in major depressive disorder. Mol Psychiatry 2015; 21: 444.
3. Mostafavi S, Battle A, Zhu X, Potash JB, Weissman MM, Shi J et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Mol Psychiatry 2014; 19: 1267–1274.
4. CONVERGE consortium. Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature 2015; 523: 588–591.
5. Ditzen C, Tang N, Jastorff AM, Teplytska L, Yassouridis A, Maccarrone G et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 2012; 37: 1013–1025.
6. Lu S, Peng H, Wang L, Vasish S, Zhang Y, Gao W et al. Elevated specific peripheral cytokines found in major depressive disorder patients with childhood trauma exposure: A cytokine antibody array analysis. Compr Psychiatry 2013; 54: 953–961.
7. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2012; 2: e87.
8. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH et al. A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 230–233.
9. Xu HB, Fang L, Hu ZC, Chen YC, Chen JJ, Li FF et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res 2012; 200: 1054–1057.
10. Xu HB, Zhang RF, Luo D, Zhou Y, Wang Y, Fang L et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int J Neuropsycho-pharmacol 2012; 15: 1413–1425.
11. Bot M, Chan MK, Jansen R, Lamers F, Vogelzangs N, Steiner J et al. Serum pro-teomic profiling of major depressive disorder. Transl Psychiatry 2015; 5: e599.
12. Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X et al. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry 2012; 2: e65.
13. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 2010; 5: e9166.
14. Stelzhammer V, Haenisch F, Chan MK, Cooper JD, Steiner J, Steeb H et al. Pro-teomic changes in serum of first onset, antidepressant drug-naive major depression patients. Int J Neuropsychopharmacol 2014; 17: 1599–1608.
15. Zheng P, Wang Y, Chen L, Yang DY, Meng HQ, Zhou DZ et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics 2013; 12: 207–214.
16. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002; 7: 254–275.
17. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11: 129.
18. Hickman RJ, Khambaty T, Stewart JC. C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J Behav Med 2014; 37: 621–629.
19. Rudolf S, Greggersen W, Kahl KG, Huppe M, Schweiger U. Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. Psychiatry Res 2014; 217: 34–38.
20. Glaus J, Vandeleur C, Gholam-Rezaee M, Castelao E, Perrin M, Rothen S et al. Atypical depression and alcohol misuse are related to the cardiovascular risk in the general population. Acta Psychiatr Scand 2013; 128: 282–293.
21. Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121–140.
22. Lamers F, de Jonge P, Nolen WA, Smit JH, Zitman FG, Beekman AT et al. Identi-fying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2010; 71: 1582–1589.
23. World Health Organization. Composite International Diagnostic Interview, Core Version 21: Interviewer's Manual. World Health Organization: Sydney, Australia, 1997.
24. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477–486.
25. Lamers F, Rhebergen D, Merikangas KR, de JP, Beekman AT, Penninx BW. Stability and transitions of depressive subtypes over a 2-year follow-up. Psychol Med 2012; 42: 2083–2093.
26. Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry 1996; 53: 391–399.
27. Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. Am J Psychiatry 1998; 155: 1398–1406.
28. Sullivan PF, Prescott CA, Kendler KS. The subtypes of major depression in a twin registry. J Affect Disord 2002; 68: 273–284.
29. Rodgers S, Ajdacic-Gross V, Muller M, Hengartner MP, Grosse HM, Angst J et al. The role of sex on stability and change of depression symptom subtypes over 20 years: a latent transition analysis. Eur Arch Psychiatry Clin Neurosci 2014; 264: 577–588.
30. Lamers F, Burstein M, He JP, Avenevoli S, Angst J, Merikangas KR. Structure of major depressive disorder in adolescents and adults in the US general population. Br J Psychiatry 2012; 201: 143–150.
31. Lamers F, Beekman ATF, van Hemert AM, Schoevers RA, Penninx BWJH. Six-year longitudinal course and outcomes of subtypes of depression. Br J Psychiatry 2016; 208: 62–68.
32. Babor TF, JRDI Fuente, Saunders J, Grant M. The Alcohol Use Disorders Identification Test: Guidelines for Use In Primary Health Care. World Health Organization: Geneva, Switzerland, 1992.
33. Bot M, Chan MK, Jansen R, Lamers F, Vogelzangs N, Steiner J et al. Serum pro-teomic profiling of major depressive disorder. Transl Psychiatry 2015; 5: e599.
34. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118–127.
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289–300.
36. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing Available at http://www R-project org/2014.
37. Mi H, Thomas P. PANTHER pathway: an ontology-based pathway database cou-pled with data analysis tools. Methods Mol Biol 2009; 563: 123–140.
38. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013; 41(Database issue): D377–D386.
39. Gecici O, Kuloglu M, Atmaca M, Tezcan AE, Tunckol H, Emul HM et al. High serum leptin levels in depressive disorders with atypical features. Psychiatry Clin Neurosci 2005; 59: 736–738.
40. Milaneschi Y, Lamers F, Bot M, Drent ML, Penninx BW, Leptin Dysregulation Is. Specifically associated with major depression with atypical features: evidence for a mechanism connecting obesity and depression. Biol Psychiatry 2015; doi:10.1016/j.biopsych.2015.10.023.
41. Lu XY. The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr Opin Pharmacol 2007; 7: 648–652.
42. Mocking RJ, Lok A, Assies J, Koeter MW, Visser I, Ruhe HG et al. Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism in recurrent depression: associations with fatty acid concentrations and waist circumference. PLoS ONE 2013; 8: e82980.
43. Bezchlibnyk YB, Xu L, Wang JF, Young LT. Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res 2007; 1147: 213–217.
44. Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Korner A et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997; 22: 493–503.
45. Conboy L, Varea E, Castro JE, Sakouhi-Ouertatani H, Calandra T, Lashuel HA et al. Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol Psychiatry 2011; 16: 533–547.
46. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment. J Affect Disord 2011; 134: 217–225.
47. Bloom J, Al-Abed Y. MIF: mood improving/inhibiting factor? J Neuroinflamm 2014; 11: 11.
48. Edwards KM, Bosch JA, Engeland CG, Cacioppo JT, Marucha PT. Elevated mac-rophage migration inhibitory factor (MIF) is associated with depressive symptoms, blunted cortisol reactivity to acute stress, and lowered morning cortisol. Brain Behav Immun 2010; 24: 1202–1208.
49. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 2013; 18: 692–699.
50. Maes M, Scharpe S, Meltzer HY, Suy E, Cosyns P, Calabrese J. Lower angiotensin I converting enzyme activity in melancholic subjects: a pilot study. Biol Psychiatry 1992; 32: 621–624.
51. Murck H, Schussler P, Steiger A. Renin-angiotensin-aldosterone system: the for-gotten stress hormone system: relationship to depression and sleep. Pharma-copsychiatry 2012; 45: 83–95.
52. Joyce PR, Hawes CR, Mulder RT, Sellman JD, Wilson DA, Boswell DR. Elevated levels of acute phase plasma proteins in major depression. Biol Psychiatry 1992; 32: 1035–1041.
53. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005; 64: 1371–1377.
54. Verwey NA, Schuitemaker A, van der Flier WM, Mulder SD, Mulder C, Hack CE et al. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 26: 522–527.
55. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997; 66: 1–11.
56. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 1994; 30: 283–288.
57. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res 1997; 43: 529–534.
58. Taylor VH, Macqueen GM. The role of adipokines in understanding the associations between obesity and depression. J Obes 2010; 2010: 6; doi:10.1155/2010/748048.
59. Cizza G, Nguyen VT, Eskandari F, Duan Z, Wright EC, Reynolds JC et al. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. J Clin Psychiatry 2010; 71: 1079–1087.
60. Diniz BS, Teixeira AL, Campos AC, Miranda AS, Rocha NP, Talib LL et al. Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res 2012; 46: 1081–1085.
61. Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honka-lampi K et al. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand 2010; 121: 209–215.
62. Leo R, Di LG, Tesauro M, Cola C, Fortuna E, Zanasi M et al. Decreased plasma adiponectin concentration in major depression. Neurosci Lett 2006; 407: 211–213.
63. Narita K, Murata T, Takahashi T, Kosaka H, Omata N, Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neu-ropsychopharmacol Biol Psychiatry 2006; 30: 1159–1162.
64. Zeugmann S, Quante A, Heuser I, Schwarzer R, Anghelescu I. Inflammatory bio-markers in 70 depressed inpatients with and without the metabolic syndrome. J Clin Psychiatry 2010; 71: 1007–1016.
65. Takeuchi T, Nakao M, Kachi Y, Yano E. Association of metabolic syndrome with atypical features of depression in Japanese people. Psychiatry Clin Neurosci 2013; 67: 532–539.
66. Mantyselka P, Korniloff K, Saaristo T, Koponen H, Eriksson J, Puolijoki H et al. Association of depressive symptoms with impaired glucose regulation, screen-detected, and previously known type 2 diabetes: findings from the Finnish D2D Survey. Diabetes Care 2011; 34: 71–76.
67. Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O et al. Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Psychiatry 2014; 17: 1381–1391.
68. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW et al. Over-weight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220–229.
69. Hasler G, Pine DS, Gamma A, Milos G, Ajdacic V, Eich D et al. The associations between psychopathology and being overweight: a 20-year prospective study. Psychol Med 2004; 34: 1047–1057.
70. Lasserre AM, Glaus J, Vandeleur CL, Marques-Vidal P, Vaucher J, Bastardot F et al. Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a Prospective, Population-Based Study. JAMA Psychiatry 2014; 71: 880–888.
71. Milaneschi Y, Lamers F, Mbarek H, Hottenga JJ, Boomsma DI, Penninx BW. The effect of FTO rs9939609 on major depression differs across MDD subtypes. Mol Psychiatry 2014; 19: 960–962.
72. Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga JJ et al. Polygenic dissection of major depression clinical heterogeneity. Mol Psychiatry 2015; 21: 516–522.
73. Angst J, Gamma A, Benazzi F, Silverstein B, Jdacic-Gross V, Eich D et al. Atypical depressive syndromes in varying definitions. Eur Arch Psychiatry Clin Neurosci 2006; 256:44–54.
74. Parker G, Roy K, Mitchell P, Wilhelm K, Malhi G, Hadzi-Pavlovic D. Atypical depression: a reappraisal. Am J Psychiatry 2002; 159: 1470–1479.